Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2007 1
2008 2
2009 2
2010 5
2014 4
2015 4
2016 6
2017 6
2018 12
2019 13
2020 22
2021 18
2022 26
2023 18
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

122 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean hongmin tu (21 results)?
CDK15 promotes colorectal cancer progression via phosphorylating PAK4 and regulating β-catenin/ MEK-ERK signaling pathway.
Huang C, Du R, Jia X, Liu K, Qiao Y, Wu Q, Yao N, Yang L, Zhou L, Liu X, Xiang P, Xin M, Wang Y, Chen X, Kim DJ, Dong Z, Li X. Huang C, et al. Cell Death Differ. 2022 Jan;29(1):14-27. doi: 10.1038/s41418-021-00828-6. Epub 2021 Jul 14. Cell Death Differ. 2022. PMID: 34262144 Free PMC article.
Colorectal cancer (CRC) is the third most diagnosed cancer and the second leading cause of cancer-related deaths. However, there are few effective therapeutic targets for CRC patients. Here, we found that CDK15 was highly expressed in human CRC and negatively correlated wi …
Colorectal cancer (CRC) is the third most diagnosed cancer and the second leading cause of cancer-related deaths. However, there are few eff …
Costunolide is a dual inhibitor of MEK1 and AKT1/2 that overcomes osimertinib resistance in lung cancer.
Tian X, Wang R, Gu T, Ma F, Laster KV, Li X, Liu K, Lee MH, Dong Z. Tian X, et al. Mol Cancer. 2022 Oct 6;21(1):193. doi: 10.1186/s12943-022-01662-1. Mol Cancer. 2022. PMID: 36203195 Free PMC article.
Remarkably, the combination of osimertinib and costunolide showed synergistic or additive inhibitory effects on tumor growth in osimertinib-resistant cell lines and PDX model. Hence, this study highlights a potential therapeutic strategy for osimertinib-resistant patients …
Remarkably, the combination of osimertinib and costunolide showed synergistic or additive inhibitory effects on tumor growth in osimertinib- …
Inhibition of USP1 activates ER stress through Ubi-protein aggregation to induce autophagy and apoptosis in HCC.
Wang L, Hu T, Shen Z, Zheng Y, Geng Q, Li L, Sha B, Li M, Sun Y, Guo Y, Xue W, Xuan D, Chen P, Zhao J. Wang L, et al. Cell Death Dis. 2022 Nov 10;13(11):951. doi: 10.1038/s41419-022-05341-3. Cell Death Dis. 2022. PMID: 36357365 Free PMC article.
The deubiquitinating enzyme USP1 (ubiquitin-specific protease 1) plays a role in the progression of various tumors, emerging as a potential therapeutic target. This study aimed to determine the role of USP1 as a therapeutic target in hepatocellular carcinoma (HCC). …
The deubiquitinating enzyme USP1 (ubiquitin-specific protease 1) plays a role in the progression of various tumors, emerging as a potential …
Cdc2-like kinases: structure, biological function, and therapeutic targets for diseases.
Song M, Pang L, Zhang M, Qu Y, Laster KV, Dong Z. Song M, et al. Signal Transduct Target Ther. 2023 Apr 7;8(1):148. doi: 10.1038/s41392-023-01409-4. Signal Transduct Target Ther. 2023. PMID: 37029108 Free PMC article. Review.
The dysregulation of these processes is linked with various diseases, including neurodegenerative diseases, Duchenne muscular dystrophy, inflammatory diseases, viral replication, and cancer. Thus, CLKs have been considered as potential therapeutic targets, and significant …
The dysregulation of these processes is linked with various diseases, including neurodegenerative diseases, Duchenne muscular dystrophy, inf …
SRSF2 mutations in myelodysplasia/myeloproliferative neoplasms.
Aujla A, Linder K, Iragavarapu C, Karass M, Liu D. Aujla A, et al. Biomark Res. 2018 Sep 26;6:29. doi: 10.1186/s40364-018-0142-y. eCollection 2018. Biomark Res. 2018. PMID: 30275952 Free PMC article. Review.
SRSF2 mutations appear to play an important role in pathogenesis of MMOS, particularly in chronic myelomonocytic leukemia. Inhibition of splicing may be a new therapeutic approach. E7107, a spliceosome inhibitor, has been shown to differentially inhibit splicing more in SR …
SRSF2 mutations appear to play an important role in pathogenesis of MMOS, particularly in chronic myelomonocytic leukemia. Inhibition of spl …
Novel immunomodulatory drugs and neo-substrates.
Gao S, Wang S, Song Y. Gao S, et al. Biomark Res. 2020 Jan 9;8:2. doi: 10.1186/s40364-020-0182-y. eCollection 2020. Biomark Res. 2020. PMID: 31938543 Free PMC article. Review.
Recent studies showed that IMiDs bind to CRBN, a substrate receptor of CRL4 E3 ligase, to induce the ubiquitination and degradation of IKZF1 and IKZF3 in multiple myeloma cells, contributing to their anti-myeloma activity. Similarly, lenalidomide exerts therapeutic efficac …
Recent studies showed that IMiDs bind to CRBN, a substrate receptor of CRL4 E3 ligase, to induce the ubiquitination and degradation of IKZF1 …
NUMA1 modulates apoptosis of esophageal squamous cell carcinoma cells through regulating ASK1-JNK signaling pathway.
Yin S, Zhao S, Li J, Liu K, Ma X, Zhang Z, Wang R, Tian J, Liu F, Song Y, Song M, Zhao R, Yang R, Lee MH, Dong Z. Yin S, et al. Cell Mol Life Sci. 2023 Jul 18;80(8):211. doi: 10.1007/s00018-023-04854-0. Cell Mol Life Sci. 2023. PMID: 37462735
Esophageal squamous cell carcinoma (ESCC) is a common malignancy worldwide with a low survival rate due to a lack of therapeutic targets. Here, our results showed that nuclear mitotic apparatus protein 1 (NUMA1) transcript and protein levels are significantly upregulated i …
Esophageal squamous cell carcinoma (ESCC) is a common malignancy worldwide with a low survival rate due to a lack of therapeutic targ …
Diagnostic performance and prognostic value of circulating tumor DNA methylation marker in extranodal natural killer/T cell lymphoma.
Tian XP, Zhang YC, Lin NJ, Wang L, Li ZH, Guo HG, Ma SY, An MJ, Yang J, Hong YH, Wang XH, Zhou H, Li YJ, Rao HL, Li M, Hu SX, Lin TY, Li ZM, Huang H, Liang Y, Xia ZJ, Lv Y, Liu YY, Duan ZH, Chen QY, Wang JN, Cai J, Xie Y, Ong CK, Liu F, Liu YY, Yan Z, Huang L, Tao R, Li WY, Huang HQ, Cai QQ. Tian XP, et al. Cell Rep Med. 2023 Feb 21;4(2):100859. doi: 10.1016/j.xcrm.2022.100859. Cell Rep Med. 2023. PMID: 36812892 Free PMC article.
We construct a diagnostic prediction model based on ctDNA methylation markers with both high specificity and sensitivity and close relevance to tumor staging and therapeutic response. Subsequently, we built a prognostic prediction model showing excellent performance, and i …
We construct a diagnostic prediction model based on ctDNA methylation markers with both high specificity and sensitivity and close relevance …
122 results